Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum
Authors:
- Flor M. MunozFMFlor M. Munoz
- Richard Md BeigiRBRichard Md Beigi
- Christine M. PosavadCPChristine M. Posavad
- Clifton KellyCKClifton Kelly
- Martina L. BadellMBMartina L. Badell
- Katherine BungeKBKatherine Bunge
- Mark J. MulliganMMMark J. Mulligan
- Lalitha ParameswaranLPLalitha Parameswaran
- Barbra A. RichardsonBRBarbra A. Richardson
- Courtney Olsen-ChenCOCourtney Olsen-Chen
- Richard M. NovakRichard M. Novak
- Rebecca C. BradyRBRebecca C. Brady
- 13 August 2024
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 43 (11) , 1065-1073
Abstract
Background: Following maternal COVID-19 vaccination, the persistence of antibodies in sera and breast milk for mothers and infants is not well characterized. We sought to describe the persistence of antibodies through 2 months after delivery in maternal and infant serum and breast milk following maternal COVID-19 mRNA vaccination and to examine differences by receipt of booster dose during pregnancy or postpartum. Methods: This is a prospective cohort study with enrollment from July 2021 to January 2022 at 9 US academic sites. Pregnant or postpartum participants and their infants were enrolled after COVID-19 mRNA monovalent vaccination during pregnancy (primary 2-dose series) with booster (third dose) vaccination during pregnancy or within 2 months post-partum. SARS-CoV-2–binding and functional antibody responses at delivery and 2 months after delivery in mothers and infants were measured by spike and receptor-binding domain immunoglobulin (Ig) G, pseudovirus and live neutralizing antibody (nAb) titers to ancestral and Omicron BA.1 and BA.5 strains. Breast milk spike and receptor-binding domain IgG and IgA titers were also measured. Results: A total of 237 maternal/infant dyads were included (110 primary series during pregnancy, 99 pregnancy booster and 28 postpartum booster). A pregnancy booster resulted in 2.2-4.7-fold higher IgG and nAb at delivery and 2 months for both mothers and infants compared to the primary series alone (P < 0.001 for all comparisons). While infant IgG and nAb titers decreased by 2 months of age, the proportion of infants with detectable nAb at 2 months was greater in infants of mothers boosted during pregnancy compared with primary series for all variants (D614G: 99% vs. 56%; BA.1: 56% vs. 4% and BA.5: 57% vs. 9%; P < 0.001 for all comparisons). Breast milk spike IgA and IgG were present in 64%-100% and 100% of participants, respectively, and those boosted during pregnancy or postpartum had 3.1-4.6-fold higher levels of breast milk antibodies at 2 months compared to primary series during pregnancy (P < 0.001). Conclusions: mRNA COVID-19 monovalent booster vaccination during pregnancy results in significantly higher maternal and infant serum–binding IgG and nAb titers compared to a primary 2-dose series, including against Omicron variants, through 2 months of age. Breast milk antibodies following maternal vaccination during pregnancy or postpartum may provide additional protection during early infancy.Keywords
This publication has 27 references indexed in Scilit:
- Vaccination from the early second trimester onwards gives a robust SARS-CoV-2 antibody response throughout pregnancy and provides antibodies for the neonateInternational Journal of Infectious Diseases, 2023
- Vaccination against SARS-CoV-2 in pregnancy during the Omicron wave: the prospective cohort study of the Italian obstetric surveillance systemClinical Microbiology and Infection, 2023
- SARS-CoV-2 vaccine booster elicits robust prolonged maternal antibody responses and passive transfer to the offspring via the placenta and breastmilkAmerican Journal of Obstetrics & Gynecology MFM, 2022
- Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United StatesJAMA Network Open, 2022
- COVID-19 booster dose induces robust antibody response in pregnant, lactating, and nonpregnant womenAmerican Journal of Obstetrics and Gynecology, 2022
- Durability of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural InfectionJAMA, 2022
- Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samplesJournal of Immunological Methods, 2021
- Selective functional antibody transfer into the breastmilk after SARS-CoV-2 infectionCell Reports, 2021
- Kinetics of maternal pertussis-specific antibodies in infants of mothers vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancyVaccine, 2020
- Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trialThe Lancet Infectious Diseases, 2016